Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01448239 · ClinicalTrials.gov registry record · Phase 1
Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01448239 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 24 participants.
The verdict
NCT01448239, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Primary Objective: Injection Site Tolerability Secondary Objectives: * To assess the safety profile of alirocumab SAR236553 (REGN727) * To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
Interventions
- DRUG alirocumab SAR236553 (REGN727)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01448239
The ClinicalTrials.gov registry entry for NCT01448239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alirocumab SAR236553 (REGN727) is the first listed.
NCT01448239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01448239 about?
NCT01448239 is a clinical study titled "Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)". Primary Objective: Injection Site Tolerability Secondary Objectives: * To assess the safety profile of alirocumab SAR236553 (REGN727) * To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
What is the current status of trial NCT01448239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01448239?
The interventions under investigation include: alirocumab SAR236553 (REGN727) (DRUG).
Who is sponsoring clinical trial NCT01448239?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.